Undeterred efforts are reported and still continue in future to achieve the goals of virologic suppression in HIV-infected individuals. Dolutegravir is the result of all the efforts made in this direction. It is a recent integrase inhibitor drug approved by the US FDA (Food and Drug Administration) for use in the treatment-naïve and treatment-experienced HIV-infected patients. This article has reviewed all the aspects of the drug, including the structural and functional analyses, in vitro activity, pharmacokinetics, drug-drug interactions, MOA, metabolism, excretion, dosing/adverse effects and resistance profile. Dolutegravir is a potent and well tolerated antiretroviral agent that can play an important role in the treating patients harboring resistance to other antiretrovirals. Some new combinations of drug with other antiretrovirals are also in the pipeline that can increase the immunologic response of the HIV
Dolutegravir; Antiretroviral; Integrase inhibitor; Human Immunodeficiency Virus (HIV)
Promoter CAG is more efficient than hepatocyteâ€‘targeting TBG for transgene expression via rAAV8 in liver tissues.
Kang J, Hang L, Zheng W, Luo J, Zhang X, Song Y, Liu A
Molecular medicine reports. 2022; 25(1):
Biovalue in Human Brain Banking: Applications and Challenges for Research in Neurodegenerative Diseases.
Methods in molecular biology (Clifton, N.J.). 2022; 2389(): 209-220
Growth differentiation factor 5: a neurotrophic factor with neuroprotective potential in Parkinson's disease.
Goulding SR, Anantha J, Collins LM, Sullivan AM, O'Keeffe GW
Neural regeneration research. 2022; 17(1): 38-44
Differentiating Human Pluripotent Stem Cells to Vascular Endothelial Cells for Regenerative Medicine, Tissue Engineering, and Disease Modeling.
Bertucci T, Kakarla S, Kim D, Dai G
Methods in molecular biology (Clifton, N.J.). 2022; 2375(): 1-12
New insights into Epsteinâ€‘Barr virusâ€‘associated tumors: Exosomes (Review).
Chen W, Xie Y, Wang T, Wang L
Oncology reports. 2022; 47(1):